IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
StockNews.AI · 3 hours
AI Summary
Insight Molecular Diagnostics reports AJT publication showing the CM-score's diagnostic advantage over dd-cfDNA alone, with PPV at 81% and NPV at 91%. The data bolster GraftAssure's commercial case and underscore a potential shift toward in-hospital dd-cfDNA testing, supported by the GALACTIC registry and a forthcoming FDA decision on GraftAssureDx.
Sentiment Rationale
Positive validation data, potential FDA clearance for GraftAssureDx, and CMS reimbursement support could drive a near-term re-rating as adoption at transplant centers accelerates.
Trading Thesis
Bullish in 3-6 months on potential FDA approval and rapid adoption of CM-score.
Market-Moving
- AJT publication validates CM-score's superiority, potential revenue catalyst.
- FDA approval timing for GraftAssureDx is a near-term catalyst.
- CMS reimbursement for GraftAssureCore supports in-house testing adoption.
- ATC 2026 presentation window could spark investor interest.
Key Facts
- CM-score outperforms dd-cfDNA in AJT pre-proof. PPV 81%, NPV 91%.
- Validated in 81 rejections, 282 non-rejections; full cohort: 106 rejections, 308 non-rejections.
- GALACTIC registry underway to confirm findings and guide decisions.
- FDA marketing authorization anticipated; IMDx aims to commercialize GraftAssureDx.
Companies Mentioned
- Insight Molecular Diagnostics, Inc. (IMDX): Publishes positive CM-score data; near-term catalysts include FDA clearance for GraftAssureDx and GALACTIC registry validation.
- Centers for Medicare & Medicaid Services (CMS): Reimbursement for GraftAssureCore supports local, in-house testing adoption and revenue potential.
- U.S. Food and Drug Administration (FDA): Marketing authorization for GraftAssureDx is a key near-term regulatory milestone.
- American Journal of Transplantation (AJT): Publication of CM-score pre-proof provides peer-reviewed validation and credibility.
- American Transplant Congress (ATC): Presentations June 2026 could raise visibility and investor interest in IMDX.
Industry News
Industry News: Highlights validation of a diagnostic, plus regulatory and commercialization milestones that can materially affect IMDX's adoption and revenue trajectory.